United States (US) IVD Analyzers Market Outlook to 2033: Hematology Analyzers, Polymerase Chain Reaction (PCR) Systems, Point of Care (POC) Analyzers and Others

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$4995
Buy Report

Published: June 23, 2025 Report Code: GDME25600CCDB-ST

Select Item

GlobalData’s “United States IVD Analyzers Market Outlook to 2033” is a comprehensive databook report, covering key market data on the United States IVD Analyzers market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Hematology Analyzers, Polymerase Chain Reaction (PCR) Systems, Point of Care (POC) Analyzers, Clinical Chemistry Analyzers, Integrated Clinical Chemistry & Immunochemistry Analyzers, Immunochemistry Analyzers and Next Generation Sequencers

The United States IVD Analyzers Market report provides key information and data on –
• Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
• 2024 company share data for IVD Analyzers Market.
• Global corporate-level profiles of key companies operating within the United States IVD Analyzers Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

United States IVD Analyzers is segmented as follows – _x000D_

• Hematology Analyzers_x000D_

• Polymerase Chain Reaction (PCR) Systems_x000D_

• Point of Care (POC) Analyzers_x000D_

• Clinical Chemistry Analyzers_x000D_

• Integrated Clinical Chemistry & Immunochemistry Analyzers_x000D_

• Immunochemistry Analyzers_x000D_

• Next Generation Sequencers

Reasons to Buy

The United States IVD Analyzers Market report helps you to develop –

• Business strategies by identifying the key market segments poised for strong growth in the future.

• Market-entry and market expansion strategies.

• Design competition strategies by identifying who-stands-where in the market.

• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

• Understand the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 7

|1.2 List of Figures 7

2 Introduction 8

2.1 What Is This Report About? 8

2.2 IVD Analyzers Market Segmentation 8

2.3 Definitions of Markets Covered in the Report 9

3 IVD Analyzers Market, United States 13

3.1 IVD Analyzers Market, United States, Revenue ($m), 2018-2033 13

3.1.1 Clinical Chemistry Analyzers Market, United States, Revenue ($m), by Segment, 2018-2033 15

3.1.2 Hematology Analyzers Market, United States, Revenue ($m), by Segment, 2018-2033 17

3.1.3 Immunochemistry Analyzers Market, United States, Revenue ($m), by Segment, 2018-2033 19

3.1.4 Next Generation Sequencers Market, United States, Revenue ($m), by Segment, 2018-2033 21

3.1.5 Point of Care (POC) Analyzers Market, United States, Revenue ($m), by Segment, 2018-2033 23

3.1.6 Polymerase Chain Reaction (PCR) Systems Market, United States, Revenue ($m), by Segment, 2018-2033 25

3.2 IVD Analyzers Market, United States, Volume (Units), 2018-2033 27

3.2.1 Clinical Chemistry Analyzers Market, United States, Volume (Units), by Segment, 2018-2033 29

3.2.2 Hematology Analyzers Market, United States, Volume (Units), by Segment, 2018-2033 31

3.2.3 Immunochemistry Analyzers Market, United States, Volume (Units), by Segment, 2018-2033 33

3.2.4 Next Generation Sequencers Market, United States, Volume (Units), by Segment, 2018-2033 35

3.2.5 Point of Care (POC) Analyzers Market, United States, Volume (Units), by Segment, 2018-2033 37

3.2.6 Polymerase Chain Reaction (PCR) Systems Market, United States, Volume (Units), by Segment, 2018-2033 39

3.3 IVD Analyzers Market, United States, Average Price ($) , 2018-2033 41

3.4 IVD Analyzers Market, United States, Company Share by Revenue ($m), 2024 45

4 Overview of Key Companies in United States, IVD Analyzers Market 47

4.1 Danaher Corp 47

4.1.1 Company Overview 47

4.2 Siemens Healthineers AG 47

4.2.1 Company Overview 47

4.3 F. Hoffmann-La Roche Ltd 47

4.3.1 Company Overview 47

4.4 Abbott Laboratories 47

4.4.1 Company Overview 47

4.5 Sysmex Corp 48

4.5.1 Company Overview 48

4.6 Bio-Rad Laboratories Inc 48

4.6.1 Company Overview 48

4.7 Agilent Technologies Inc 48

4.7.1 Company Overview 48

4.8 Thermo Fisher Scientific Inc 48

4.8.1 Company Overview 48

4.9 Quidelortho Corp 49

4.9.1 Company Overview 49

4.10 Hologic Inc 49

4.10.1 Company Overview 49

5 IVD Analyzers Market Pipeline Products 50

6 Financial Deals Landscape 63

6.1 Acquisition 63

6.1.1 Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories 63

6.2 Debt Offerings 65

6.2.1 Laboratory Corp of America Holdings Raises USD650 Million in Public Offering of

4.35% Notes Due 2030 65

6.2.2 Laboratory Corp of America Holdings Raised Public Offering of

4.55% Notes Due 2032 for USD500 Million 67

6.2.3 Laboratory Corp of America Holdings Raises USD850 Million in Public Offering of

4.8% Notes Due 2034 69

6.2.4 Agilent Technologies Raises USD600 Million in Public Offering of

4.200% Senior Notes Due 2027 71

7 Recent Developments 72

7.1 Corporate Communications 72

7.1.1 Apr 23, 2025: Huiyu Pharmaceutical’s Clinical Trial Application for Innovative Biological Drug HY-0005 Has Been Accepted 72

7.1.2 Mar 18, 2025: NeoGenomics Appoints Warren Stone as President & Chief Operating Officer 73

7.1.3 Nov 21, 2024: United Imaging Announces the First of Several New U.S. Product Launches For RSNA 73

7.1.4 Aug 20, 2024: Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer 74

7.1.5 Jun 12, 2024: MaxCyte Announces Result of AGM 74

7.2 Financial Announcements 75

7.2.1 Apr 22, 2025: Quest Diagnostics Announces Results for Q1 Ended March 31, 2025 75

7.2.2 Apr 08, 2025: NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025 75

7.2.3 Mar 13, 2025: Zomedica Announces Record Revenue and Strategic Growth in 2024 75

7.2.4 Feb 26, 2025: Zomedica Announces Upcoming Financial Results Conference Call 75

7.2.5 Feb 18, 2025: NeoGenomics Reports Fourth Quarter and Full Year 2024 Results 76

7.2.6 Feb 07, 2025: MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference 76

7.2.7 Jan 29, 2025: NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025 77

7.2.8 Jan 28, 2025: Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call 77

7.2.9 Jan 22, 2025: Baxter to Host Fourth-Quarter 2024 Financial Results Conference Call for Investors 77

7.2.10 Jan 10, 2025: Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results 77

7.2.11 Oct 25, 2024: Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results 78

7.2.12 Oct 16, 2024: Baxter to Host Third-Quarter 2024 Financial Results Conference Call for Investors 78

7.2.13 Oct 16, 2024: Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call 79

7.2.14 Sep 24, 2024: Labcorp to Announce Third Quarter Financial Results on October 24, 2024 79

7.2.15 Aug 13, 2024: Syntec Optics to Host Conference Call to Discuss Financial Results and Business Update 79

7.2.16 Aug 08, 2024: Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results 79

7.2.17 Aug 06, 2024: MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance 79

7.2.18 Jul 17, 2024: Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors 81

7.2.19 Jul 09, 2024: NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024 81

7.2.20 Jun 27, 2024: Abbott Hosts Conference Call for Second-Quarter Earnings 81

7.2.21 Jun 19, 2024: Quest Diagnostics to Release Second Quarter 2024 Financial Results on July 23, 2024 81

7.3 Government and Public Interest 82

7.3.1 Feb 24, 2025: NeoGenomics to Participate in Upcoming Investor Conferences 82

7.3.2 Feb 17, 2025: Baxter to Present at Raymond James & Associates’ 46th Annual Institutional Investors Conference 82

7.3.3 Feb 07, 2025: MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference 82

7.3.4 Dec 18, 2024: Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference 82

7.3.5 Nov 12, 2024: Baxter to Present at Stifel 2024 Healthcare Conference 82

7.3.6 Aug 29, 2024: NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference 83

7.3.7 Aug 28, 2024: Baxter to Present at 2024 Wells Fargo Healthcare Conference 83

7.4 Legal And Regulatory 83

7.4.1 Mar 19, 2025: Sonnet Receives Notice of Allowance for U.S. Patent Covering Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein 83

7.4.2 Mar 07, 2025: Medtronic Neuromodulation Received Humanitarian Device Exemption (HDE) For Percept PC BrainSense Neurostimulator Model – B35200 84

7.4.3 Jan 13, 2025: VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 84

7.4.4 Dec 18, 2024: Howmedica Osteonics Receives Additional 510(K) Clearance For AVON Patello-Femoral Joint Prosthesis 86

7.4.5 Dec 18, 2024: Positive Results Advance Peanut Tablet to Phase II Development 86

7.4.6 Dec 10, 2024: Enterome’s EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to ‘Watchful Waiting 87

7.4.7 Nov 19, 2024: Botanix presentation at Bell Potter Healthcare Conference 89

7.5 Other Significant Developments 90

7.5.1 Apr 30, 2025: AdjuTec Pharma’s APC148 Shines at ESCMID Congress 90

7.5.2 Feb 05, 2025: UMC Utrecht Adopts Volta Labs Callisto Sample Prep System to Process Thousands of Samples for Whole Genome Sequencing-Based Prenatal and Postnatal Testing 90

7.5.3 Jun 13, 2024: Intelligent Bio Solutions Implements Strategic Reorganization Plan to Support Global Growth Initiatives 91

7.5.4 May 30, 2024: ChromaTan Receives a $2M Phase IIB NIH Grant to Develop a Fully Integrated Continuous Purification of AAV via BioRMB – a Column-Free Steady-State Continuous Elution Purification Platform 91

7.6 Product News 92

7.6.1 May 06, 2025: DCN Dx Launches Redesigned Website to Improve Access to Resources, Showcase Team 92

7.6.2 Apr 24, 2025: Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag AAV Reagent 92

7.6.3 Apr 22, 2025: Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development 93

7.6.4 Apr 01, 2025: Waters Announces Expansion of Alliance iS Bio HPLC Product Line 94

7.6.5 Mar 03, 2025: BrightSpec Launches World's First Commercial MRR Instruments in 50 Years at PittCon 2025 95

7.6.6 Jan 24, 2025: Curiox Biosystems Launches Curiox C- Free Pluto ALPHA: Affordable, Hassle-Free Cell Washing Automation 96

7.6.7 Jan 22, 2025: Targeted Bioscience Unveils Revolutionary Extracellular Vesicle Isolation Kit 96

7.6.8 Jan 15, 2025: RID Launches a One-Button Solution for Microbiology Testing That Provides Pathogen ID and Antibiotic Sensitivity in 5 Hours 97

7.6.9 Dec 02, 2024: Bruker Announces Launch of Dimension Nexus Atomic Force Microscope 97

7.6.10 Nov 07, 2024: Waters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness 98

7.6.11 Oct 17, 2024: Charles River Launches New Retrogenix Non-human Protein Library 98

7.6.12 Oct 14, 2024: BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research 99

7.6.13 Oct 03, 2024: Harvard Bioscience to Showcase Innovative Technologies at Society for Neuroscience (SfN) Annual Meeting 2024 100

7.6.14 Oct 01, 2024: Thermo Fisher Scientific Introduces Mass Spectrometers to Simplify Trace Elemental Analysis and Enhance Productivity 101

7.6.15 Sep 17, 2024: Charles River Comparative Study Reveals that Kytopen's Flowfect Tx Platform Outperforms Conventional Electroporation Platforms 101

7.6.16 Aug 29, 2024: Nikon Announces New Image Analysis Functions to Empower Drug Discovery Research for Cancer, Neurological Disease, and Regenerative Medicine 102

7.6.17 Aug 14, 2024: Bruker Announces Successful Installation of

1.2 GHz Avance NMR Spectrometer at the Korea Basic Science Institute (KBSI) 104

7.6.18 Aug 07, 2024: Bio-Rad Launches Annexin V StarBright Conjugates for Apoptosis Detection via Flow Cytometry 105

7.6.19 Jul 25, 2024: Thermo Fisher Scientific Showcases Diagnostics Innovation Across Therapeutic Areas at ADLM 2024 105

7.6.20 Jun 27, 2024: Nikon Introduces Newly Developed Imaging Technology for Greatly Accelerated Speed and Efficiency in Research for Biotechnology 107

7.6.21 Jun 27, 2024: Zomedica Expands Truforma Addressable Market with Launch of Equine Cortisol Assay for the Platform 108

7.7 Strategy And Business Planning 108

7.7.1 May 13, 2025: Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics 108

7.7.2 Apr 25, 2025: Bioskryb Genomics and Tecan Introduce a Single-Cell Multiomics Workflow for Sequencing-Ready Libraries in Under Ten Hours 109

7.7.3 Feb 28, 2025: BioChain Announces Strategic Partnership With Spatomics 109

7.7.4 Oct 02, 2024: Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica to Advance the Discovery of Novel Drugs for Neurological Disease 110

7.7.5 Sep 23, 2024: Angle PLC Announces Exclusive Agreement for DNA NGS Panel 110

7.7.6 Sep 14, 2024: RYBREVANT (Amivantamab) Plus Chemotherapy Show 49 Percent Overall Response Rate in Metastatic Colorectal Cancer 111

7.7.7 Jul 01, 2024: Artel Portfolio Expands Presence in Europe 113

7.7.8 Jun 25, 2024: Curiox Biosystems Announces the Establishment of the Curiox Innovation Center for the Curiox C-FREE Pluto LT System at Stanford University's Human Immune Monitoring Center 113

7.7.9 Jun 21, 2024: DNA Diagnostics Center Announces Collaboration With Contraline 113

7.7.10 May 29, 2024: Nikon Instruments Announces Opening of Research Innovation Hub and BioImaging Lab in Lexington, Massachusetts 114

8 Appendix 115

8.1 Research Methodology 116

8.1.1 Coverage 116

8.1.2 Secondary Research 116

8.1.3 Primary Research 116

8.1.4 Market Modeling and Forecasting 117

8.1.5 Company Share Analysis 118

8.1.6 Benchmarking 119

8.2 GlobalData Consulting 120

8.3 Contact Us 120

8.4 Disclaimer 120

Table

Table 1: IVD Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 14

Table 2: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 16

Table 3: Hematology Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 18

Table 4: Immunochemistry Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 20

Table 5: Next Generation Sequencers Market, United States, Revenue ($m), USD Constant, 2018-2033 22

Table 6: Point of Care (POC) Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 24

Table 7: Polymerase Chain Reaction (PCR) Systems Market, United States, Revenue ($m), USD Constant, 2018-2033 26

Table 8: IVD Analyzers Market, United States, Volume (Units), 2018-2033 28

Table 9: Clinical Chemistry Analyzers Market, United States, Volume (Units), 2018-2033 30

Table 10: Hematology Analyzers Market, United States, Volume (Units), 2018-2033 32

Table 11: Immunochemistry Analyzers Market, United States, Volume (Units), 2018-2033 34

Table 12: Next Generation Sequencers Market, United States, Volume (Units), 2018-2033 36

Table 13: Point of Care (POC) Analyzers Market, United States, Volume (Units), 2018-2033 38

Table 14: Polymerase Chain Reaction (PCR) Systems Market, United States, Volume (Units), 2018-2033 40

Table 15: IVD Analyzers Market, United States, Average Price ($), 2018-2033 41

Table 16: IVD Analyzers Market, United States, Company Share by Revenue ($m), 2024 46

Table 17: IVD Analyzers Market Pipeline Products 50

Table 18: Searle Denies Rumour to Acquire 51% Stake in Abbott Laboratories 63

Table 19: Laboratory Corp of America Holdings Raises USD650 Million in Public Offering of 4.35% Notes Due 2030 65

Table 20: Laboratory Corp of America Holdings Raised Public Offering of 4.55% Notes Due 2032 for USD500 Million 67

Table 21: Laboratory Corp of America Holdings Raises USD850 Million in Public Offering of 4.8% Notes Due 2034 69

Table 22: Agilent Technologies Raises USD600 Million in Public Offering of 4.200% Senior Notes Due 2027 71

Table 23: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country 117

Figures

Figure 1: IVD Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 13

Figure 2: Clinical Chemistry Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 15

Figure 3: Hematology Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 17

Figure 4: Immunochemistry Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 19

Figure 5: Next Generation Sequencers Market, United States, Revenue ($m), USD Constant, 2018-2033 21

Figure 6: Point of Care (POC) Analyzers Market, United States, Revenue ($m), USD Constant, 2018-2033 23

Figure 7: Polymerase Chain Reaction (PCR) Systems Market, United States, Revenue ($m), USD Constant, 2018-2033 25

Figure 8: IVD Analyzers Market, United States, Volume (Units), 2018-2033 27

Figure 9: Clinical Chemistry Analyzers Market, United States, Volume (Units), 2018-2033 29

Figure 10: Hematology Analyzers Market, United States, Volume (Units), 2018-2033 31

Figure 11: Immunochemistry Analyzers Market, United States, Volume (Units), 2018-2033 33

Figure 12: Next Generation Sequencers Market, United States, Volume (Units), 2018-2033 35

Figure 13: Point of Care (POC) Analyzers Market, United States, Volume (Units), 2018-2033 37

Figure 14: Polymerase Chain Reaction (PCR) Systems Market, United States, Volume (Units), 2018-2033 39

Figure 15: IVD Analyzers Market, United States, Company Share (%), 2024 45

United States (US) IVD Analyzers Market Outlook to 2033: Hematology Analyzers, Polymerase Chain Reaction (PCR) Systems, Point of Care (POC) Analyzers and Others standard reports
Currency USD
$4,995

Can be used by individual purchaser only

Most Popular
$9,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports
Medical Devices
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Medical Devices
New
Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…
$495 | July 2026
Medical Devices
New
AI-designed Materials: Market Trends and Innovations
$995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at United States (US) IVD Analyzers Market Outlook to 2033: Hematology Analyzers, Polymerase Chain Reaction (PCR) Systems, Point of Care (POC) Analyzers and Others in real time.

  • Access a live United States (US) IVD Analyzers Market Outlook to 2033: Hematology Analyzers, Polymerase Chain Reaction (PCR) Systems, Point of Care (POC) Analyzers and Others dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more